PCLAF and cancer: The most important observation of this study is that the pCR achieved with the NCT regimens (cyclophosphamide/doxorubicin or cyclophosphamide/epirubicin) is associated with a significant decrease in the gene expression levels of NUSAP1 and PCLAF. The association between clinical outcomes and transcriptional profile is consistent with the fact that the expression of these genes is involved in mitosis and DNA replication, respectively (Figure 2), fundamental processes involved in cancer progression, as will be discussed later.